Octávio Costa
Geen lopende functies
Profiel
Octávio Costa served as Chief Medical Officer at Cornerstone Pharmaceuticals, Inc. and Monopar Therapeutics, Inc. before earning a doctorate degree from Pontifícia Universidade Católica de São Paulo.
Eerdere bekende functies van Octávio Costa
| Bedrijven | Functie | Einde |
|---|---|---|
Cornerstone Pharmaceuticals, Inc.
 Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | Hoofd Techniek/Wetenschap/O&O | - |
| MONOPAR THERAPEUTICS INC. | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Octávio Costa
| Pontifícia Universidade Católica de São Paulo | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| MONOPAR THERAPEUTICS INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | Commercial Services |
